Clinical Trial Links Specific Probiotic Strain to Improved Sleep Quality and Energy

Industry Pulse News Desk · 2026-10-17

Clinical Trial Links Specific Probiotic Strain to Improved Sleep Quality and Energy

A study involving adults with mild depression found that daily supplementation with Bifidobacterium longum 1714 led to measurable enhancements in rest and daily vigor.

A specific strain of probiotic bacteria, Bifidobacterium longum 1714, has demonstrated measurable improvements in sleep quality and daily energy levels among adults experiencing mild depression, according to newly published clinical research. The findings highlight the growing focus on microbiome-based therapies for sleep regulation.

Investigators evaluated the impact of the bacterial strain during a structured clinical trial involving adult participants who met criteria for subclinical or mild depressive symptoms. Over the course of the study, participants ingested daily oral doses of the live microorganism while researchers systematically monitored physiological and psychological parameters.

The data revealed that while participants experienced minor shifts in overall mood indicators, the most pronounced and statistically significant improvements occurred in sleep metrics and daytime stamina. Subjective evaluations and clinical tracking showed reduced nocturnal disruptions, improved sleep efficiency, and enhanced daytime wakefulness.

Bifidobacterium longum 1714 is categorized as a psychobiotic, a specialized class of live organisms that, when ingested in adequate amounts, confer mental health benefits through interaction with the gut-brain axis. Researchers suggest that neural and metabolic signaling originating in the gastrointestinal tract may directly influence sleep-wake architecture.

Authors of the study noted that while the current results are promising for individuals with low-grade mood disorders, further clinical evaluation is necessary. Subsequent trials will aim to determine long-term treatment efficacy, optimal administration protocols, and whether similar benefits extend to general populations suffering from primary insomnia.